1. Home
  2. CVSA vs XENE Comparison

CVSA vs XENE Comparison

Compare CVSA & XENE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CVSA

Covista Inc. Common Shares

N/A

Current Price

$116.22

Market Cap

3.9B

Sector

Real Estate

ML Signal

N/A

XENE

Xenon Pharmaceuticals Inc.

HOLD

Current Price

$58.49

Market Cap

3.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CVSA
XENE
Founded
1987
1996
Country
United States
Canada
Employees
4996
N/A
Industry
Other Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.9B
3.2B
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
CVSA
XENE
Price
$116.22
$58.49
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
12
Target Price
$150.00
$67.17
AVG Volume (30 Days)
248.0K
1.0M
Earning Date
05-07-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$311,000.00
Revenue This Year
$9.66
N/A
Revenue Next Year
$6.58
$2,436.26
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$96.08
$28.19
52 Week High
$118.80
$62.91

Technical Indicators

Market Signals
Indicator
CVSA
XENE
Relative Strength Index (RSI) 61.10 61.73
Support Level $110.97 $39.93
Resistance Level $118.80 $59.44
Average True Range (ATR) 3.42 1.83
MACD -0.59 -0.22
Stochastic Oscillator 67.97 72.68

Price Performance

Historical Comparison
CVSA
XENE

About CVSA Covista Inc. Common Shares

Covista Inc is an American healthcare educator, serving more than 97,000 students and supported by a community of alumni across five accredited institutions. Through personalized, tech-enabled education powered by faculty and colleagues, it expands access to healthcare careers and addresses the U.S. healthcare workforce shortage at scale.

About XENE Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.

Share on Social Networks: